UK First to Grant License for Teva’s Ophthalmology Biosimilar Ongavia For Wet AMD

Teva Pharmaceutical said it welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia, a biosimilar to Lucentis (ranibizumab).

UK First to Grant License for Teva’s Ophthalmology Biosimilar Ongavia For Wet AMD
May 20, 2022
Efficacy of Notal Vision Home OCT Proven by a Series of Scientific and Clinical Work

Notal Vision reported that scientific and clinical publications and presentations demonstrate the feasibility and efficacy of their patient-operated, home-based optical coherence tomography (OCT) device.

Efficacy of Notal Vision Home OCT Proven by a Series of Scientific and Clinical Work
July 01, 2022
Study Finds Up to 30% of Patients with Wet AMD Can Safely Stop Anti-VEGF Treatment

According to Johns Hopkins Medicine researchers, up to a third of people with "wet" age-related macular degeneration might be able to safely quit eye injection therapy without further vision loss.

Study Finds Up to 30% of Patients with Wet AMD Can Safely Stop Anti-VEGF Treatment
January 19, 2022
Outlook Therapeutics Announces FDA Acceptance of BLA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics announced that the FDA accepted for filing a Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration.

Outlook Therapeutics Announces FDA Acceptance of BLA for ONS-5010 as a Treatment for Wet AMD
October 31, 2022
FDA Approves Genentech’s Vabysmo to Treat Wet AMD and DME

The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), marking the first bispecific antibody approved for the eye.

FDA Approves Genentech’s Vabysmo to Treat Wet AMD and DME
February 02, 2022
More